

By Senator Fasano

11-00340A-09

20092650\_\_

1                   A bill to be entitled  
2       An act relating to pharmaceutical take-back programs;  
3       creating s. 499.0295, F.S.; requiring drug  
4       manufacturers who sell drugs in this state to  
5       establish a take-back program that accepts and  
6       disposes of pharmaceuticals turned in by consumers by  
7       a certain date; provides program requirements;  
8       requires the manufacturer to submit a program plan to  
9       the Department of Health, which must review and  
10      approve or reject the plan; requiring retail  
11      pharmacies to post a sign informing consumers about  
12      the take-back program; requiring a manufacturer to pay  
13      a fee to the department designed to cover the  
14      department's administrative costs for the program;  
15      authorizing the department to impose administrative  
16      fines for violations; establishing an advisory  
17      committee to advise the department on issues relating  
18      to take-back programs; providing for member  
19      appointment, terms, selection of a chairperson, number  
20      of meetings, and reimbursement for expenses;  
21      authorizing the department to adopt rules; providing  
22      an effective date.

23  
24 Be It Enacted by the Legislature of the State of Florida:

25  
26       Section 1. Section 499.0295, Florida Statutes, is created  
27 to read:

28       499.0295 Pharmaceutical take-back program.-

29       (1) Effective July 1, 2011, a manufacturer of a drug may

11-00340A-09

20092650

30 not sell the drug or allow the drug to be sold in this state  
31 unless the manufacturer operates a pharmaceutical take-back  
32 program approved by the department. The take-back program must:

33 (a) Accept prescription and proprietary drugs presented to  
34 the program by consumers, including residents of long-term care  
35 facilities and persons enrolled in hospice and home health  
36 programs;

37 (b) Accept all prescription and proprietary drugs sold in  
38 this state regardless of manufacturer;

39 (c) Offer pharmaceutical take-back services at no cost to  
40 the consumer at the time of sale of the drug or at the time of  
41 collection of the drug;

42 (d) Be convenient and adequate to serve consumers in urban  
43 and rural areas;

44 (e) Dispose of collected drugs by incineration or hazardous  
45 waste disposal;

46 (f) Include an education and outreach program to inform  
47 consumers, retail pharmacies, health practitioners, county  
48 health departments, hospitals, hospice care providers, and long-  
49 term care facilities of the availability of the program; and

50 (g) Include a method for evaluation and improvement of the  
51 program.

52 (2) A manufacturer may operate its pharmaceutical take-back  
53 program individually or collectively with other manufacturers.

54 (3) A manufacturer that sells drugs in this state shall  
55 submit a plan describing the manufacturer's proposed  
56 pharmaceutical take-back program to the department for approval.

57 The plan must:

58 (a) Describe how the program meets the requirements of

11-00340A-09

20092650\_\_

59 subsection (1);

60 (b) Include recovery goals for the first 3 years of the  
61 program, expressed as pounds per capita, and a plan for action  
62 if the recovery goals are not met;

63 (c) Describe the proposed method for disposal of the  
64 collected drugs;

65 (d) Describe how the manufacturer will coordinate with  
66 other manufacturers to minimize consumer confusion about  
67 different pharmaceutical take-back programs;

68 (e) Meet other requirements established by rule of the  
69 department; and

70 (f) Be accompanied by a fee determined by the department  
71 under subsection (9).

72 (4) Within 60 days after a manufacturer submits a plan  
73 under subsection (3), the department shall approve or reject the  
74 plan. If the plan is rejected, the department shall provide the  
75 manufacturer with a written statement of the reasons for the  
76 rejection, and the manufacturer may submit a revised plan within  
77 60 days after the date of the written statement of rejection.  
78 The department shall approve or reject the revised plan within  
79 60 days after its submission.

80 (5) Following department approval, the manufacturer shall  
81 submit an updated plan to the department annually, on or before  
82 the anniversary of the approval of the original plan. The  
83 department shall review the disposal proposal in the updated  
84 plan, and shall approve or reject the updated plan as provided  
85 in subsection (4).

86 (6) If at the time the plan is due for submission to the  
87 department there is no legal method for a manufacturer to accept

11-00340A-09

20092650

88 all prescription and proprietary drugs through the  
89 pharmaceutical take-back program, a manufacturer may apply to  
90 the department for an extension of the time to submit the plan.  
91 The department may grant an extension for up to 1 year.

92 (7) The department may withdraw approval of a plan if a  
93 manufacturer does not operate the manufacturer's pharmaceutical  
94 take-back program in accordance with the approved plan.

95 (8) Retail pharmacies must post a sign informing consumers  
96 of the availability of pharmaceutical take-back programs. The  
97 department shall make an example of the sign available on the  
98 department's website.

99 (9) The department shall adopt rules establishing the  
100 application fee for submission of a pharmaceutical take-back  
101 program plan. The application fee may not exceed the costs  
102 incurred by the department in regulating pharmaceutical take-  
103 back programs, including the cost of any full-time employees  
104 necessary to administer the program.

105 (10) The department may impose administrative penalties for  
106 violations of this section as established by rule which may not  
107 exceed \$500 per violation.

108 (11) Moneys received under subsections (9) and (10) shall  
109 be used to support the program.

110 (12) There is created the Advisory Committee on  
111 Pharmaceutical Take-Back Programs, consisting of seven members  
112 appointed by the State Health Officer who shall serve at the  
113 pleasure of the officer. The advisory committee shall advise the  
114 department on issues relating to pharmaceutical take-back  
115 programs.

116 (a) The term of office of each member is 3 years except

11-00340A-09

20092650

117 that some members of the first council may serve shorter terms  
118 in order to establish staggered terms. A member is eligible for  
119 reappointment for one additional term.

120 (b) The advisory committee shall elect one of its members  
121 to serve as chairperson.

122 (c) The advisory committee shall meet at least four times  
123 per year, at times and places specified by the call of the  
124 chairperson or of a majority of the members of the advisory  
125 committee.

126 (d) A member of the committee shall serve without  
127 compensation, but is entitled to reimbursement for per diem and  
128 travel expenses incurred in the performance of duties related to  
129 the committee in accordance with s. 112.061.

130 (e) All state agencies are directed to assist the advisory  
131 committee in the performance of its duties and to furnish such  
132 information and advice as the members of the advisory committee  
133 consider necessary to perform their duties.

134 (13) The department may adopt rules to administer this  
135 section.

136 Section 2. This act shall take effect July 1, 2009.